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extent of tumor resection, and postoperative 
radiotherapy. However, the LTS patients 
were substantially younger in age 
(Supplementary Table 1, available online). 
Methylation-specific polymerase chain 
reaction analysis of CpGs within the MGMT 
promoter region revealed that methylation 
was observed in substantially more LTS 
tumors than STS tumors (P = .181, 
two-sided Fisher exact test). This finding is 
in agreement with previous data showing 
that MGMT promoter hypermethylation 
was nearly twice as common in glioblas-
tomas from LTS compared with glioblas-
tomas from patients with more typical 
average survival times of about 12 months (4). 
DNA sequencing analysis (Supplementary 
Methods, available online) of tumor series 
for mutations in IDH1 codon 132 for argi-
nine (R132) and IDH2 codon 172 for argi-
nine (R172) revealed mutations in nine of 11 
(one R132C and eight R132H codon substi-
tutions) LTS tumors, but in zero of 12 STS 
tumors (P < .001, two-sided Fisher’s exact 
test). IDH2 mutations were absent in both 
LTS and STS tumors. These data lend fur-
ther support to the strong association of 
IDH1 mutation with younger age and longer 
overall survival in primary glioblastoma 
patients (6,7,9).
Glioblastomas from LTS and STS were 
analyzed for mRNA expression using two 
different formats of the same oligonucleo-
tide microarray platform, and two datasets 
were generated (Supplementary Methods, 
available online). To minimize experi-
mental bias, a hypothesis was developed 
based on dataset 1 (n = 7 STS tumors and 
n = 7 LTS tumors) and validated using 
dataset 2 (n = 5 STS tumors and n = 4 LTS 
tumors), rather than pooling the raw data 
(Supplementary Methods, available online). 
Significance analysis of microarrays of 
dataset 1 identified 30 genes that were dif-
ferentially expressed in LTS and STS 
tumors (Supplementary Table 2, available 
online); calculations were performed with-
out applying a fold-change cutoff to iden-
tify genes with small but consistent changes. 
Three of the 30 genes have been described 
previously to participate in retinoic acid 
(RA) signaling—retinol binding protein 1 
(RBP1), retinoic acid receptor responder 2 
(RARRES2), and fatty acid–binding protein 
Glioblastoma is the most common and most 
malignant primary brain tumor in adults (1). 
The prognosis is poor as indicated by a me-
dian survival of less than 12 months in a 
population-based study (2); however, a small 
fraction (3%–5%) of patients survive for 36 
months or longer—these patients are known 
as long-term survivors (LTS) (3). These 
patients are usually younger than 50 years at 
the time of diagnosis, are in good clinical 
condition, and mostly have tumors with 
promoter hypermethylation of the DNA 
repair gene O-6-methylguanine-DNA 
methyltransferase (MGMT) (3,4). In addi-
tion, mutations in the isocitrate dehydroge-
nase 1 and 2 (IDH1 and IDH2) genes have 
recently been reported in a subset of glio-
blastomas from younger patients and linked 
to a more favorable survival outcome (5–7). 
Nevertheless, the molecular and cellular 
mechanisms underlying the rare phenom-
enon of long-term survival in glioblastoma 
patients are not known.
To investigate the possible intrinsic dif-
ferences in activation of different signaling 
pathways, in this study, we performed a 
comparative genome-wide expression 
profiling of patient tumors from 11 LTS 
(referred to as LTS tumors) and 12 
short-term survivors (STS) (referred to as 
STS tumors) by microarray analysis 
(Supplementary Methods, available online). 
Written informed consent was obtained 
from the patients, and follow-up data were 
retrospectively determined and linked to 
molecular data in an anonymous manner as 
approved by the institutional review boards 
of the Medical Faculties of the Heinrich-
Heine-University, Düsseldorf, Germany, 
and the University of Dresden, Dresden, 
Germany. The patient groups were bal-
anced for Karnofsky performance score (8), 
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Although the prognosis of most glioblastoma patients is poor, 3%–5% patients show 
long-term survival of 36 months or longer after diagnosis. To study the differences in 
activation of biochemical pathways, we performed mRNA and protein expression 
analyses of primary glioblastoma tissues from 11 long-term survivors (LTS; overall 
survival ≥ 36 months) and 12 short-term survivors (STS; overall survival ≤ 6 months). 
The mRNA expression ratio of the retinoic acid transporters fatty acid–binding protein 
5 (FABP5) and cellular retinoic acid–binding protein 2 (CRABP2), which regulate the 
differential delivery of retinoic acid to either antioncogenic retinoic acid receptors or 
prooncogenic nuclear receptor peroxisome proliferator–activated receptor delta, was 
statistically significantly higher in the tumor tissues of STS than those of LTS (median 
ratio in STS tumors = 3.64, 10th–90th percentile = 1.43–4.54 vs median ratio in LTS 
tumors = 1.42, 10th–90th percentile = 20.98 to 2.59; P < .001). High FABP5 protein ex-
pression in STS tumors was associated with highly proliferating tumor cells and acti-
vation of 3-phosphoinositide-dependent protein kinase-1 and v-akt murine thymoma 
viral oncogene homolog. The data suggest that retinoic acid signaling activates dif-
ferent targets in glioblastomas from LTS and STS. All statistical tests were two-sided.
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5 (FABP5) (10). We investigated the 
mRNA expression of each of these three 
genes in dataset 1 and found that expression 
levels were higher in STS tumors (n = 7) 
compared with LTS tumors (n = 7) (P < .001 
for RBP1, P = .017 for RARRES2, P = .004 
for FABP5; two-sided Student t test) 
(Figure 1, A–C), suggesting that there was 
a difference in RA signaling between the 
two groups. Analysis of dataset 2 indepen-
dently confirmed these findings (data not 
shown).
RBP1 stabilizes RA and transports it 
from the liver to the cells of the peripheral 
tissues (11). For nuclear import, RA is 
bound to cellular retinoic acid–binding 
protein 2 (CRABP2) and delivered to the 
nuclear retinoic acid receptors (RARs) (12). 
Activation of RARs typically leads to differ-
entiation (13), cell cycle arrest (14), apo-
ptosis (15,16), and consequently to reduced 
cell proliferation (10). Recently, an alterna-
tive pathway of RA action was identified 
involving binding and transport of RA into 
the cell nucleus by FABP5, resulting in cell 
survival and proliferation via activation of 
peroxisome proliferator–activated receptor 
delta (PPARD) (10). Which of these diverse 
pathways is activated depends on the ratio 
of the respective transport proteins, FABP5 
and CRABP2 (10). A low FABP5 to 
CRABP2 ratio leads to predominant RAR 
activation, whereas a high ratio results in 
preferential activation of PPARD.
In both datasets 1 and 2, CRABP2 
mRNA expression did not differ between 
LTS and STS tumors (data not shown); 
however, because of consistent overexpres-
sion of FABP5 mRNA in STS tumors, sta-
tistically significantly elevated FABP5 to 
CRABP2 gene expression ratios were 
obtained in these tumors compared with 
LTS tumors (median ratio in STS tumors = 
3.64, 10th–90th percentile = 1.43–4.54 vs 
median ratio in LTS tumors = 1.42, 10th–
90th percentile = 20.98 to 2.59; P < .001; 
two-sided Student t test) (Figure 1, D). 
FABP5 to CRABP2 mRNA expression 
ratios did not correlate with age at diagnosis 
CONTEXT AND CAVEATS
Prior knowledge
Approximately 3%–5% of glioblastoma 
patients survive 36 months or longer (long-
term survivors [LTS]) compared with a 
median survival of less than 12 months 
(short-term survivors [STS]) for 95%–97% 
glioblastoma patients.
Study design
The intrinsic differences in activation of 
different signaling pathways between LTS 
and STS tumors were examined by micro-
array analysis of mRNA expression and in 
vitro immunohistochemical analysis of 
protein expression of 11 LTS and 12 STS 
tumors.
Contribution
The mRNA expression of three retinoic acid 
signaling genes was statistically signifi-
cantly increased in STS tumors. Retinoic 
acid signaling via cellular retinoic acid–
binding protein 2 (CRABP2) is involved in 
differentiation and reduced cell prolifera-
tion, whereas signaling via fatty acid–bind-
ing protein 5 (FABP5) is involved in cell 
survival and proliferation, which pathway 
gets activated depends on the FABP5/
CRABP2 ratio. CRABP2 expression was sim-
ilar in LTS and STS tumors, but a statistically 
significantly increased FABP5 expression 
was noted in STS tumors. The levels of the 
prosurvival proteins 3-phosphoinositide-
dependent protein kinase-1 and v-akt murine 
thymoma viral oncogene homolog were 
also increased in STS tumors.
Implications
A differential retinoic acid signaling in LTS 
and STS tumors may be the reason for 
increased proliferation and reduced sur-
vival of STS tumors and could be used as a 
therapeutic target.
Limitations
The results are based on a small sample 
size and in vitro data.
From the Editors
 
Figure 1. Analysis of mRNA expression of retinoic acid signaling genes in long-term survivors of 
glioblastoma (LTS) and short-term survivors of glioblastoma (STS) tumors. Two different for-
mats of oligonucleotide microarrays were used to generate two different datasets. Microarray 
analysis was performed once per sample. A) Box plot showing the mRNA expression of retinol 
binding protein 1 (RBP1) in LTS tumors (n = 7) and STS tumors (n = 7) (dataset 1). B) Box plot 
showing the mRNA expression of retinoic acid receptor responder 2 (RARRES2) in LTS tumors 
(n = 7) and STS tumors (n = 7) (dataset 1). C) Box plot showing the mRNA expression of fatty 
acid–binding protein 5 (FABP5) in LTS tumors (n = 7) and STS tumors (n = 7) (dataset 1). D) Box 
plot showing the ratios of FABP5 to retinoic acid–binding protein 2 (CRABP2) mRNA expression 
in the combined datasets 1 and 2 of LTS tumors (n = 11) and STS tumors (n = 12). Medians, 25th 
to 75th percentiles and 10th to 90th percentiles are indicated by the horizontal lines, boxes, and 
error bars, respectively. In addition, the outliers are displayed as dots. P values were calculated 
using two-sided Student t test. 
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in either group (for LTS, Spearman’s rank 
correlation coefficient rho [r] = 20.027, P = 
.924; for STS, r = 0.007, P = .974). 
Consistent with the proposed regulatory 
role of FABP5 to CRABP2 ratio in glioblas-
toma, the mRNA expression of the RAR 
target genes retinoic acid receptor beta 
(RARB) and cytochrome P450, family 26, 
subfamily A, polypeptide 1 (CYP26A1) was 
substantially higher in LTS tumors com-
pared with STS tumors (for RARB, P = 
.005; for CYP26A1, P = .029; two-sided 
Student t test) (Supplementary Figure 1, 
available online). Increased FABP5 expres-
sion in STS tumors at the protein level was 
confirmed using immunohistochemistry 
(Figure 2, A and B). Costaining the tumor 
sections for the proliferation marker Ki67 
protein showed that FABP5-positive cells 
clustered exclusively in highly proliferative 
tumor regions from STS patients (Figure 2, 
A). FABP5 expression was generally low in 
LTS tumors (Figure 2, B). Double staining 
for glial fibrillary acidic protein, a marker of 
astrocytic cells, showed that FABP5 was 
expressed in STS tumor cells (Figure 1, C) 
but not in CD34-positive endothelial cells 
(Figure 1, D). One of the main transcrip-
tional targets of PPARD is the 3-phos-
phoinositide-dependent protein kinase-1 
(PDPK1), which activates the v-akt murine 
thymoma viral oncogene homolog (AKT). 
AKT in turn promotes cell survival and in-
hibits apoptosis by a variety of signaling 
routes (17,18). Activation of the AKT sig-
naling pathway in STS tumors was con-
firmed by immunohistochemical detection 
of high levels of phosphorylated PDPK1 in 
10 of 12 STS tumors, but none of 11 LTS 
tumors (Figure 2, E and F). This was further 
confirmed by immunoblot analysis 
(Supplementary Figure 2, available online), 
which showed higher ratios of phosphory-
lated AKT to total AKT level in STS 
tumors (mean ratio = 0.88; 95% confidence 
interval = 0.66 to 1.10) than in LTS tumors 
(mean ratio = 0.29; 95% confidence interval 
= 0.18 to 0.40).
Although RA exerts anticarcinogenic 
properties mainly by activating the nuclear 
RARs (retinoic acid receptor alpha, RARB, 
retinoic acid receptor gamma) via the fatty 
acid transporter CRABP2, its use in cancer 
therapy is rather limited because of acquisi-
tion of resistance to RA during pathogen-
esis (19). Indeed, in some cancers, RA is 
known to promote rather than reduce 
tumor growth (10,20). In malignant glioma, 
RA treatment revealed heterogeneous 
results (21,22). Our data indicate that the 
majority of glioblastomas may not be re-
ceptive to RA treatment because of the 
observed high FABP5 to CRABP2 ratios in 
these tumors. Moreover, in glioblastomas, 
endogenous RA may be sufficient to enforce 
malignant progression through activation 
of multiple antiapoptotic signaling cascades 
mediated by FABP5 to PPARD ratios, 
thereby possibly worsening the patient out-
come. Therefore, pharmacological inhibi-
tion of FABP5, PPARD, or AKT signaling 
may allow bypassing of the adverse effects 
of RA treatment in glioblastoma patients.
Our findings provide evidence for a 
distinct molecular mechanism associated 
with long-term survival of glioblastoma, 
which could be exploited in the design of 
new treatment strategies for these still in-
curable tumors. However, this study has 
limitations such as small sample size and 
exclusive reliance on in vitro data. Further 
investigations using RA therapy in cell cul-
ture and in vivo models of LTS and STS 
glioblastoma are necessary to conclusively 
support our findings.
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